Integrin receptor antagonists
    4.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号:US5710159A

    公开(公告)日:1998-01-20

    申请号:US647132

    申请日:1996-05-09

    摘要: This invention relates to novel heterocycle compounds including but not limited to 3-�3-�3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.

    摘要翻译: 本发明涉及包括但不限于3- [3- [3-(咪唑啉-2-基氨基)丙氧基]异恶唑-5-基羰基氨基] -2-(苄氧基羰基氨基) - 丙酸的新型杂环化合物,其可用作 αvβ3和相关整联蛋白受体的拮抗剂,含有这些化合物的药物组合物,制备此类化合物的方法,以及使用这些化合物单独或与其它治疗剂组合用于抑制细胞粘附和 血管生成障碍,炎症,骨退化,肿瘤,转移,血栓形成和其他细胞聚集相关病症的治疗。